Eiji Kutoh
Kumagaya, 3600023, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Differential modulation of adipose tissue insulin resistance by modified traditional Japanese diet and SGLT-2 inhibitor canagliflozin in type 2 diabetes.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: June 21, 2025
Diverse Strategies for Modulating Insulin Resistance: Causal or Consequential Inference on Metabolic Parameters in Treatment-Naïve Subjects with Type 2 Diabetes.
Journal: Medicina (Kaunas, Lithuania)
Published: May 27, 2024
Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.
Journal: European journal of clinical pharmacology
Published: April 24, 2023
Regulation of Adipose Tissue Insulin Resistance and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Journal: Drug research
Published: March 07, 2023
Regulations of Free Fatty Acids and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Journal: Drug research
Published: November 03, 2021
Complementary effects on glycaemic and non-glycaemic parameters between responders and non-responders treated with pioglitazone and canagliflozin in drug-naive subjects with type 2 diabetes.
Journal: International journal of clinical practice
Published: May 15, 2021
Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes.
Journal: Drug research
Published: November 26, 2020
Link between serum uric acid and pancreatic beta-cell function in drug naïve subjects with type 2 diabetes treated with sitagliptin.
Journal: Hospital practice (1995)
Published: November 16, 2020
Link between body weight changes and metabolic parameters in drugs naïve subjects with type 2 diabetes treated with canagliflozin monotherapy.
Journal: Hospital practice (1995)
Published: February 27, 2020
Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: A potential link between uric acid and pancreatic β-cell function .
Journal: International journal of clinical pharmacology and therapeutics
Published: October 08, 2019
Efficacy and safety of dulaglutide in patients with absolute insulin deficiency.
Journal: Endocrine regulations
Published: September 14, 2019
Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.
Journal: Drugs in R&D
Published: October 17, 2018
Last Updated: 09/26/2026